Last updated on December 2019

PHIL Evaluation in the Endovascular Treatment of Intracranial Dural AVF

Brief description of study

The primary objective of this study is to demonstrate the safety and efficacy of the PHIL liquid in endovascular treatment of dural arteriovenous fistula.

Detailed Study Description

This is an European multi-center observational study. Treatments and follow-up visits will be done as per standard of care.

The objective of this study is to evaluate the efficacy and safety of the PHIL device in the treatment of intracranial dural ArterioVenous Fistula (dAVF). The PHIL device, a non-adhesive liquid embolic agent, has been CE marked since July 2014. It is intended for use in the embolization of lesions in the peripheral and neurovasculature, including arteriovenous malformations and hypervascular tumors.

All patients with an intracranial dAVF that has not been previously treated and will be treated by embolization with PHIL are eligible for this study. A maximum of 70 patients will be enrolled in this study in 16 European Institutions.

The expected approximate study duration is 38 months.

Clinical Study Identifier: NCT03317821

Find a site near you

Start Over

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.